CA3255700A1 - A scoring method for an anti-trop2 antibody‑drug conjugate therapy - Google Patents
A scoring method for an anti-trop2 antibody‑drug conjugate therapyInfo
- Publication number
- CA3255700A1 CA3255700A1 CA3255700A CA3255700A CA3255700A1 CA 3255700 A1 CA3255700 A1 CA 3255700A1 CA 3255700 A CA3255700 A CA 3255700A CA 3255700 A CA3255700 A CA 3255700A CA 3255700 A1 CA3255700 A1 CA 3255700A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- adc
- antibody
- positive
- optical density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320629P | 2022-03-16 | 2022-03-16 | |
| US63/320,629 | 2022-03-16 | ||
| PCT/IB2023/052428 WO2023175483A1 (en) | 2022-03-16 | 2023-03-14 | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3255700A1 true CA3255700A1 (en) | 2023-09-21 |
Family
ID=85776040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3255700A Pending CA3255700A1 (en) | 2022-03-16 | 2023-03-14 | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4493933A1 (https=) |
| JP (1) | JP2025509564A (https=) |
| KR (1) | KR20240165390A (https=) |
| CN (1) | CN118891525A (https=) |
| AU (1) | AU2023235490A1 (https=) |
| CA (1) | CA3255700A1 (https=) |
| IL (1) | IL315662A (https=) |
| WO (1) | WO2023175483A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026052764A1 (en) | 2024-09-06 | 2026-03-12 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody drug conjugate therapy |
| CN119986001B (zh) * | 2025-01-23 | 2026-04-07 | 中山大学孙逸仙纪念医院 | 试剂盒及其在预测trop2-adc疗效中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ATE198623T1 (de) | 1994-08-12 | 2001-01-15 | Myriad Genetics Inc | Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs |
| ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ITCH20120008A1 (it) * | 2012-05-16 | 2013-11-17 | Saverio Alberti | Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| US10241115B2 (en) * | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
| AU2014371934B2 (en) * | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| JP6980980B2 (ja) * | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| CN108601841A (zh) * | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| CN110461342A (zh) * | 2017-02-06 | 2019-11-15 | 诺华股份有限公司 | 预测对免疫疗法的反应的方法 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
-
2023
- 2023-03-14 CN CN202380027572.6A patent/CN118891525A/zh active Pending
- 2023-03-14 AU AU2023235490A patent/AU2023235490A1/en active Pending
- 2023-03-14 IL IL315662A patent/IL315662A/en unknown
- 2023-03-14 WO PCT/IB2023/052428 patent/WO2023175483A1/en not_active Ceased
- 2023-03-14 JP JP2024554777A patent/JP2025509564A/ja active Pending
- 2023-03-14 CA CA3255700A patent/CA3255700A1/en active Pending
- 2023-03-14 EP EP23713763.3A patent/EP4493933A1/en active Pending
- 2023-03-14 KR KR1020247034328A patent/KR20240165390A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118891525A (zh) | 2024-11-01 |
| JP2025509564A (ja) | 2025-04-11 |
| IL315662A (en) | 2024-11-01 |
| WO2023175483A1 (en) | 2023-09-21 |
| KR20240165390A (ko) | 2024-11-22 |
| AU2023235490A1 (en) | 2024-09-26 |
| EP4493933A1 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021340002B9 (en) | A scoring method for an anti-her2 antibody-drug conjugate therapy | |
| Cherradi et al. | Antibody targeting of claudin-1 as a potential colorectal cancer therapy | |
| Bates et al. | Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab | |
| CA2740900C (en) | Antibodies that specifically block the biological activity of a tumor antigen | |
| WO2021260583A1 (en) | Combination of antibody-drug conjugate and dna-pk inhibitor | |
| JP2014193862A (ja) | 新規な抗ｉｇｆ−ｉｒ抗体及びその使用 | |
| TWI822822B (zh) | 抗體-藥物結合物之用途 | |
| WO2022102695A1 (ja) | 抗ｂ７－ｈ３抗体－薬物コンジュゲート投与による中皮腫の治療 | |
| WO2023175483A1 (en) | A scoring method for an anti-trop2 antibody‑drug conjugate therapy | |
| JP4799863B2 (ja) | 癌制御方法 | |
| CN116997566A (zh) | 用PDGFRα抑制剂治疗癌症的方法 | |
| MX2014013931A (es) | Metodos para tratar el cancer gastrico. | |
| WO2011054112A1 (en) | Antibodies that specifically block the biological activity of kidney associated antigen 1 | |
| WO2026052764A1 (en) | A scoring method for an anti-trop2 antibody drug conjugate therapy | |
| EP4211663B1 (en) | A scoring method for an anti-b7h4 antibody-drug conjugate therapy | |
| US20250288687A1 (en) | Combination of antibody-drug conjugates and dnmt inhibitors | |
| WO2025088496A1 (en) | Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein | |
| EP3959233A1 (en) | Netrin g1 and netrin g1 ligand peptides and antibodies and uses thereof | |
| EA045144B1 (ru) | Лечение her2-мутированного рака введением конъюгата анти-her2-антитело-лекарственное средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240916 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250123 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250123 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250131 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250217 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250917 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260226 |